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Edited by B. PoolmanAbstractStructure determination of mammalian integral membrane proteins is challenging due to their instability upon
detergent solubilisation and purification. Recent successes in the structure determination of G-protein-
coupled receptors (GPCRs) resulted from the development of GPCR-specific protein engineering strategies.
One of these, conformational thermostabilisation, could in theory facilitate structure determination of other
membrane proteins by improving their tolerance to detergents and locking them in a specific conformation. We
have therefore used this approach on the cocaine-sensitive rat serotonin transporter (SERT). Out of a panel of
554 point mutants throughout SERT, 10 were found to improve its thermostability. The most stabilising
mutations were combined to make the thermostabilised mutants SAH6 (L99A + G278A + A505L) and SAH7
(L405A + P499A + A505L) that were more stable than SERT by 18 °C and 16 °C, respectively. Inhibitor
binding assays showed that both of the thermostabilised SERTmutants bound [125I]RTI55 (β-CIT) with affinity
similar to that of the wild-type transporter, although cocaine bound with increased affinity (17- to 56-fold) whilst
ibogaine, imipramine and paroxetine all bound with lower affinity (up to 90-fold). Neither SAH6 nor SAH7 was
capable of transporting [3H]serotonin into HEK293 cell lines stably expressing the mutants, although
serotonin bound to them with an apparent Ki of 155 μM or 82 μM, respectively. These data combined suggest
that SAH6 and SAH7 are thermostabilised in a specific cocaine-bound conformation, making them promising
candidates for crystallisation. Conformational thermostabilisation is thus equally applicable to membrane
proteins that are transporters in addition to those that are GPCRs.
© 2013 Elsevier Ltd. Open access under CC BY license.Introduction
Structure determination of eukaryotic integral
membrane proteins is challenging, but once the
fundamental problems of producing well-diffracting
crystals for G-protein-coupled receptors (GPCRs)
had been understood and solved,1,2 there was a
dramatic increase in the number of structures
determined. A combination of strategies developed
in a number of laboratories has underpinned GPCR
crystallisation, including the development of recep-
tor–T4 lysozyme (T4L) fusions,3,4 conformational
thermostabilisation of the GPCRs,5–9 crystallisation
in lipidic cubic phase10,11 and the use of antibody
fragments.12–14 However, the key component for
success is undoubtedly the stability of the GPCR
during purification and crystallisation.1,15 Two strat-
egies have been used successfully to improve the0022-2836 © 2013 Elsevier Ltd. Open access under CC BY license.stability of GPCRs. The addition of high-affinity
ligands to receptor–T4L fusions allowed their crystal-
lisation in lipidic cubic phase (see, e.g., Ref. 16), with
the stability of the receptor–T4L–ligand complex
being determined by a fluorescent thermostability
assay performed on the purified protein.17 An
alternative strategy is to thermostabilise the receptor
by systematic mutagenesis coupled to a thermosta-
bility assay based upon the binding of a radiolabelled
ligand. The resulting receptor usually contains four to
six thermostabilising mutations and is preferentially
in a single conformation.5,6,8,9 The advantage of the
latter strategy is that, because the receptor is
thermostabilised in a specific conformation, crystal
structures can be determined of the receptor bound
to ligands that bind only very weakly.18,19 When both
approaches have been used on identical or similar
receptors in the same conformation, the structures ofJ. Mol. Biol. (2013) 425, 2198–2207
2199Thermostabilisation of SERTthe transmembrane regions are essentially identical
(rmsd ~ 0.6 Å), although larger differences may be
observed in the loop regions due to lattice contacts
and/or the presence of T4L.1
The success of developing generic strategies for
the crystallisation of GPCRs suggests that analo-
gous developments for transporters may result in a
similar acceleration in the rate of their structure
determination. Current methodologies for the crys-
tallisation of transporters have relied on the identi-
fication of those transporters that are sufficiently
stable for purification and crystallisation.20 This has
allowed the structure determination of many trans-
porters from different families, but the majority of the
structures are of bacterial proteins.21 Clearly, purified
transporters have to be sufficiently stable in detergent
solution for structure determination; thus, application
of thermostabilisation strategies to transporters
should be possible and would facilitate structure
determination. To initiate this approach for trans-
porters, we have therefore decided to apply the
strategy of conformational thermostabilisation to the
rat serotonin transporter (SERT).22
SERT is a member of the SLC6 subclass of the
neurotransmitter sodium symporter (NSS) family.23
Members of the NSS family play important roles in
regulating neurotransmitter concentrations in the
peripheral and central nervous system by re-uptake
into the presynaptic nerve termini. Indeed, the
monoamine transporters are key targets for thera-
peutic intervention in a wide range of CNS disorders,
as well as the primary targets for drugs of abuse
such as cocaine and amphetamines.24,25 SLC6
transporters in mammals are characterised by 12
transmembrane helices with a large extracellular
loop between transmembrane helices 3 and 4 (TM3
and TM4) that is invariably N-glycosylated. Structur-
al studies on this family of transporters have focused
on bacterial homologues that are extremely stable,
such as LeuT,26 but to fully understand inhibitor
binding and the mechanism of transport of the
mammalian transporters, it is essential to determine
their structures. However, the mammalian trans-
porters are difficult targets for structural studies.
Heterologous expression of the transporters for 5HT
(SERT), GABA (GAT) and norepinephrine (NET)
using the baculovirus expression is possible,27 but
functional expression levels are low and only a
proportion of the expressed protein is correctly
folded (as defined by the binding of radiolabelled
inhibitors).28,29 It appears that the folding of these
transporters is relatively inefficient and requires the
transporter to be N-glycosylated,28 which allows
interaction with the molecular chaperone calnexin.29
A parallel study of seven different expression
systems clearly identified a tetracycline-inducible
mammalian cell line as the most efficient at
producing fully functional SERT.30 However, it was
found that SERT is unstable in detergent solution,perhaps due to its absolute requirement for
cholesterol. 31 The advantage of working with
SERT is that there is a very high affinity radiolabelled
compound available, [125I]RTI55 (β-CIT),28,32 that
allows the discrimination of functional versus mis-
folded SERT. We have therefore chosen SERT as
an ideal, although difficult, target for thermostabilisa-
tion. Here we describe the thermostabilisation
strategy and the characterisation of two thermosta-
ble mutants suitable for structural studies.Results
Development of a thermostability assay
for SERT
Conformational thermostabilisation of a mem-
brane protein requires the testing of hundreds of
mutants for thermostability, and therefore, a rapid
and simple expression system for SERT was
needed to provide sufficient transporter for the
assays. The neuronal cell line HEK293 was previ-
ously identified as the most efficient system for the
production of SERT30; thus, transient transfection
was tested using a plasmid (pcDNA3) that constitu-
tively expressed the fluorescent fusion protein
SERT-mCherry from the strong cytomegalovirus
promoter. However, despite altering the amount of
plasmid transfected between 0.1 and 1.0 μg per
50,000 cells, the vast majority of the fusion protein
appeared to be expressed intracellularly rather than
at the cell surface (Abdul-Hussein, unpublished
data). Previous work suggests that the intracellular
material is misfolded and cannot bind radiolabelled
inhibitor.30,33 Similar trials using transient transfec-
tion of SERT-mCherry expressed from a tetracy-
cline-inducible promoter pcDNA5/FRT/TO identified
0.05–0.1 μg of plasmid per 50,000 cells as the
optimal amount to ensure that the majority of SERT
was expressed at the cell surface as observed by
confocal microscopy (Fig. S1). Binding assays using
an excess of [125I]RTI55 at a concentration of 1 nM
(5 times the KD)
28 showed that there were, on
average, approximately 100,000 copies per trans-
fected cell and that there were sufficient molecules of
SERT in 50,000 cells per well of a 96-well plate to
perform a single-point thermostability assay in
duplicate (Fig. S2).
Thermostability assays usually involved adding
the radioligand to detergent-solubilised membrane
proteins,9 but the only detergent that SERT was
stable in was digitonin,34 which is unsuitable for
crystallography. Therefore, a different assay where
an inhibitor was used to stabilise the transporter was
developed. This entailed adding [125I]RTI55 to the T-
REx-SERT cells followed by detergent solubilisation
and then the thermostability assay (heating samples
2200 Thermostabilisation of SERTat various temperatures for 30 min). The apparent
Tm was defined as the temperature where 50% of the
transporter still bound the radiolabelled inhibitor (Fig.
S2). For [125I]RTI55-bound SERT, the apparent Tm
was 28 °C, regardless of how it was expressed in
HEK293 cells (Fig. S2). Note that a considerable
proportion of this thermostability is attributable to the
bound inhibitor because the apparent Tm of n-
dodecyl-β-D-maltopyranoside (DDM)-solubilised
SERT without bound [125I]RTI55 could not be
measured. [125I]RTI55-bound SERT was also sen-
sitive to the concentration of DDM present in the
assays (Fig. S2), with the apparent Tm decreasing as
the concentration of detergent increases, similar to
that observed for the β1-adrenergic receptor.
35 The
most reproducible results with the steepest thermo-Fig. 1. Thermostabilisation of SERT. (a) Comparison of [125I
either at 4 °C or after heating at 30 °C for 30 min. The data r
normalised to the amount of wild-type SERT remaining after he
wild-type SERT is indicated by the vertical broken line, and the g
[125I]RTI55 to the parental T-REx-HEK293 cell line (no SERT
50,000 cells measured in duplicate (estimated error is ±20% e
mutants were engineered by combining the best thermostabili
apparent Tm after solubilisation in 0.1% DDM. (c) Amino
thermostabilising mutations (blue or purple) that consistently
residues in purple were used to stabilise either SAH6 or SAH
hexagons, a putative disulfide bond is shown as a yellow line an
(c-Myc tag and the fluorescent reporter protein mCherry) andstability curve were obtained with a final concen-
tration of 0.1% DDM; thus, this was used in
subsequent assays to determine the thermostabil-
ity of SERT mutants. The assays were repeated
using either [3H]imipramine or [3H]paroxetine
under identical conditions. However, nonspecific
binding of both [3H]imipramine and [3H]paroxetine
to DDM micelles was very high (greater than 50%
of the total binding measured). In our experience,
this would introduce significant experimental vari-
ability during the testing of hundreds of mutants,
which would result in unreliability and the gener-
ation of numerous false positives. We therefore
used [125I]RTI55 for all subsequent thermostability
assays as background binding to DDM micelles
was negligible.]RTI55 bound to 554 detergent-solubilised Ala/Leu mutants
elating to thermostability (the heated samples) have been
ating (40%; horizontal broken line). The expression level of
rey column (0–200 dpm) represents nonspecific binding of
). Each data point represents binding to an equivalent of
xpressed in dpm). (b) The optimally thermostabilised SAH
sing mutations (as indicated) that resulted in an increased
acid sequence of SERT showing the positions of the
gave N1 °C increase in Tm compared to wild-type SERT;
7. N-linked glycosylation sites are indicated by the green
d the N-terminal and C-terminal fusion partners are shown
indicated.
Fig. 2. Detergent stability of the thermostabilised
mutants SAH6 and SAH7. (a) Thermostability curves for
[125I]RTI55-bound DDM-solubilised SAH6 (blue circles)
and SAH7 (red squares) compared to wild-type SERT
(black triangles). The apparent Tm values determined from
the curves are as follows: SAH6, 46 °C; SAH7, 44 °C;
wild-type SERT, 28 °C. All the data were collected in a
single experiment with measurements performed in
duplicate. (b) The stability of [125I]RTI55-bound SAH6,
SAH7 and wild-type SERT was compared in eight different
detergents. [125I]RTI55 was added to membranes (final
concentration, 1 nM) that were then solubilised for 30 min
on ice in the following detergents (aliphatic chain length in
parentheses; final detergent concentration, in %): 0.1%
DDM (C12), 1% DDM (C12), 0.4% DM (C10), 0.35% FC12
(C12), 0.3% LDAO (C12), 0.6% Hega-10 (C10), 0.5% NG
(C9), 0.6% NM (C9), 0.83% OG (C8). The detergent-
solubilised samples where then heated at 30 °C for 30 min
before determining the amount of SERT remaining in
relation to control (incubated on ice). Results are from a
single experiment performed in duplicate [±SEM (standard
error of the mean)] with an equivalent of 50,000 cells per
data point.
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Systematic alanine-scanning mutagenesis was
performed throughout SERT between amino acid
residues 49 and 603, with each residue changed to
alanine or if the residue was already alanine, then it
was changed to leucine. Each SERT-mCherry
mutant was sequenced to ensure that only the
desired mutation was present. A total of 554 mutants
were constructed throughout the transmembrane
domains and all loop regions (Fig. 1). The N-
terminus and C-terminus were not mutated because
these regions are predicted to be disordered and
they are therefore unlikely to contribute to the
thermostability of SERT. Each mutant was transient-
ly transfected into T-REx-HEK293 cells and expres-
sion induced by the addition of tetracycline.
Expression was assessed by fluorescence micros-
copy to ascertain whether the mutant was predom-
inantly either at the plasma membrane or
intracellular. The thermostability of each mutant
was then determined using a single-temperature
thermostability assay and compared to the thermo-
stability of wild-type SERT. Under these assay
conditions (see Materials and Methods), the sample
was heated at 28 °C for 30 min and approximately
40% of wild-type SERT remained functional. Each
batch of mutants tested contained wild-type SERT
as a control so that the data between different
experiments could be normalised (wild type = 40%).
Analysis of the results (Fig. 1) identified 34 mutations
that appeared to improve the thermostability of
SERT but that did not decrease the levels of
expression by more than 70%. Interestingly, there
was no linear correlation between the levels of
expression and thermostability of the mutants, in
contrast to in GPCRs where a weak linear correlation
was sometimes observed (r2 = 0.2).1 Of the 34
mutations identified, full thermostability curves
showed that 10 mutations improved the thermosta-
bility of SERT by at least 1 °C (Table S1). Of these
10 mutations, 7 were in the transmembrane helices
and 3 were in the extracellular loops (Fig. 1). Further
mutation of these Ala/Leu mutants to other amino
acid residues did not significantly improve the
thermostability of SERT (Fig. S3).
Combining the thermostabilising mutations in
SERT was performed by a rational process previ-
ously described for the thermostabilisation of ago-
nist-bound neurotensin receptor and adenosine A2A
receptor.5 The four best thermostabilising mutations
(P499A, A505L, L99A and G113A) were each
combined with each other to make a series of double
mutants (Table S2). Of these mutants, the most
thermostable were A505L + L99A (SAH4) and
A505L + P499A (SAH5). These double mutants
were then combined with the remaining mutants to
make triple mutants (Table S2), with the most
thermostable being SAH6 (A505L + L99A +G278A)and SAH7 (A505L + P499A + L405A) with appar-
ent Tm values of 16 °C and 18 °C higher than that
of wild-type SERT (Fig. 2). Further combinations of
mutations did not improve significantly the thermo-
stability of these mutants (Table S2); thus, SAH6
and SAH7 were identified as the best candidates
for structural studies and were therefore charac-
terised further.
Fig. 4. Thermostabilised mutants do not transport 5HT.
3
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SAH6 and SAH7
The most useful characteristic of thermostabilised
GPCRs is that they are more stable in short chain
detergents that are suitable for crystallography,1 and
both SAH6 and SAH7 were also more tolerant to
short chain detergents than wild-type SERT (Fig. 2).
Another defining characteristic of conformationally
thermostabilised GPCRs is that the receptors are
preferentially in one particular conformation (see
Discussion). Therefore, radioligand binding assays
were performed on the thermostabilised SERT
mutants. The affinity of SAH6 and SAH7 for [125I]
RTI55 in saturation ligand binding assays was found
to be largely unchanged with apparent KD values of
3.8 ± 0.1 nM and 1.3 ± 0.1 nM, respectively, com-
pared to 1.6 nM ± 0.1 nM for wild-type SERT (Fig.
S4). Competition binding assays (Fig. S4) showed
that SAH6 had an apparent affinity for cocaine 17-
fold higher than that of wild-type SERT (Fig. 3) whilst
there was a small decrease in affinity for ibogaine,
imipramine, paroxetine and serotonin (4.5-, 6.7-, 90-
and 2.9-fold, respectively). SAH7 showed a similar
profile of binding, although the absolute valuesFig. 3. Inhibitor and substrate affinities for SAH6 and
SAH7 mutants compared with wild-type SERT. Apparent
Ki values were determined from competition binding
curves (Fig. S4) and are plotted as the change in affinities
with respect to wild-type SERT (ΔpKi). Competition assays
were performed on membranes using a final concentration
of 0.2 nM [125I]RTI55 and apparent Ki values determined
using the following apparent KD values for [
125I]RTI55
binding (Fig. S4): SAH6, 3.7 ± 0.7 nM; SAH7, 1.2 ±
0.5 nM; wild-type SERT, 3.7 ± 2.2 nM. Error bars are
proportional to the standard error of the mean from the
original measurements.
(a) [ H]5HT uptake assays were performed on tetracy-
cline-induced stable T-REx cell lines expressing SAH6-
GFP (blue), SAH7-GFP (red) and SERT-GFP (green), with
nonspecific uptake determined upon addition of 10 μM
cocaine and the results baseline corrected. The results are
from a single experiment performed in triplicate [±SEM
(standard error of the mean)] with approximately 100,000
cells per data point. (b) Confocal microscope images of
cells expressing transporter-GFP fusions used in the
uptake assays in (a). No fluorescence was detected in
parental T-REx-HEK293 cells. SAH6-GFP, SAH7-GFP
and SERT-GFP were all capable of binding [125I]RTI55
binding with high affinity (Fig. S4).differed slightly (Fig. S4 and Fig. 3). Although both
SAH6 and SAH7 were capable of binding inhibitors
and the substrate serotonin, neither mutant was able
to efficiently transport [3H]5HT into the cell despite
the presence of the mutants in the plasma mem-
brane as defined by confocal microscopy (Fig. 4).Discussion
Conformational thermostabilisation of GPCRs
resulted in a shift in the equilibrium between their
two main conformations R and R*, where the R*
state can couple to G proteins.1 Thus, receptors
thermostabilised using antagonists were preferen-
tially in the R state (decreased affinity for agonists
and unchanged affinity for antagonists), whilst re-
ceptors thermostabilised with agonists were prefer-
entially in an R* state (decreased affinity for
antagonists and unchanged/increased affinity for
2203Thermostabilisation of SERTagonists). Transporters are similar to GPCRs be-
cause they exist in at least two distinct conforma-
tions, with the substrate binding site accessible to
either the extracellular environment (outward open)
or to the cytoplasm (inward open), with a number of
potential intermediate occluded states where the
substrate cannot dissociate to either side of the
membrane.36,37 Indeed, the structures of many
bacterial transporters that fit into the above scheme
have been determined, and at least in the case of
Mhp138,39 and LeuT,26,40 different conformations of
the same transporter have also been described.
With these data in mind, what do the binding studies
performed on both SAH6 and SAH7 suggest about
their respective conformations?
The affinity of [125I]RTI55 for both SAH6 and SAH7
is virtually identical with the wild-type transporter,28
which strongly supports the contention that the
mutants are folded in a biologically relevant confor-
mation. This is further supported by the cell surface
expression of both mutants in stable cell lines
expressing either SAH6 or SAH7, as misfolded
SERT is retained in the endoplasmic reticulum.
Competition assays using both inhibitors and the
substrate 5HT provide further evidence on the likely
conformation that has been stabilised. Both SAH6
and SAH7 bind cocaine with higher affinity than wild-
type SERT. None of the mutations are in the region
proposed to be the inhibitor binding site41,42; thus, in
analogy to what has been previously observed in
GPCRs, these data suggest that SAH6 and SAH7
have been stabilised in a “cocaine-bound” confor-
mation. This is perhaps unsurprising given that
cocaine represents the core structure of RTI5532
and that they therefore bind at a similar site. As
cocaine has been proposed to bind preferentially to
the outward-open conformation of SERT,43 it is likely
that both SAH6 and SAH7 are thermostabilised in an
outward-open state. The decrease in binding affinity
of both imipramine and paroxetine for SAH6 is
consistent with this interpretation, as there are likely
to be subtle differences between the binding of these
inhibitors compared to RTI55, even though they are
all proposed to bind to the outward-open state.44,45
Comparison of the affinities of inhibitor binding
shows that there are subtle differences between
SAH6 and SAH7, although why these arise is difficult
to ascertain in the absence of a structure.
A characteristic of transporters is obviously their
ability to facilitate the vectorial movement of sub-
strates across biological membranes.36,37 5HT
transport catalysed by SAH6 and SAH7 was
therefore compared with the wild-type transporter
in stable cell lines that robustly express the trans-
porters on the cell surface of a tetracycline-inducible
HEK293 cell line.30,46 Despite robust transport of
[3H]5HT facilitated by wild-type SERT, no significant
transport was observed in cell lines expressing cell-
surface-expressed SAH6 or SAH7. This is not due toalterations in the binding site for 5HT because 5HT
prevented [125I]RTI55 binding in competition assays
although the affinity for 5HT was decreased by 1.5-
to 2.9-fold. These data are consistent with the theory
that both SAH6 and SAH7 are thermostabilised in a
specific outward-open conformation. However, at
this stage, we cannot categorically confirm this, as
there is always a possibility of unexpected dynamics
of membrane proteins, which could be a result of the
paucity of structural understanding of SERT. Indeed,
ibogaine was still capable of inhibiting the binding of
[125I]RTI55 to both SAH6 and SAH7 (with a change
in Ki of either 4.5-fold or 16.5-fold, respectively)
despite the fact that ibogaine has been proposed to
bind preferentially to the inward-open conforma-
tion.47 Whether this is a reflection on the potentially
dynamic nature of the thermostabilised mutants or
insufficient understanding of the binding of ibogaine
to SERT will only be resolved convincingly upon the
structure determination of SERT.
There is a growing body of data suggesting that
the structure of SERT is very similar to that of the
bacterial transporter LeuT. Indeed, structures of
LeuT bound to antidepressant drugs that bind to
SERT have been determined41,42 and, despite the
large difference of binding affinities (millimolar
versus nanomolar), have led to plausible models
for how antidepressant drugs inhibit SERT. We have
therefore mapped the thermostabilising mutations
we have identified in this study to the structure of
LeuT bound to sertraline (Figs. S5–S7 and Fig. 5). It
is striking that all the mutations in SAH6 and SAH7
are found at the interfaces between transmembrane
α-helices and, more specifically, in either a kinked
region or in an α-helix adjacent to a kink. This is
analogous to the positions of thermostabilising
mutations in GPCRs, although in GPCRs, some
mutations were also found in amino acid residues
that point into the lipid bilayer.18,48 It is tempting to
speculate on the role of these amino acid residues in
the conformational changes in both SERT and LeuT,
but as the structure of SERT has not yet been
determined, any proposals would be highly tentative.
However, a number of observations that may lead to
fruitful avenues of investigation can be made. The
conserved nature of the amino acid residues that
have been mutated to improve the thermostability of
SERT suggests that similar mutations in related
transporters such as that for norepinephrine (NET)
and dopamine (DAT) may also improve their
thermostability, as has been observed when thermo-
stabilising mutations have been transferred between
closely related GPCRs.35 In addition, the importance
of the helix–helix interactions defined by the thermo-
stabilisation mutations may be worth investigating,
particularly, in the context of a well-studied trans-
porter such as LeuT, as this may facilitate our
understanding of the dynamics of these transporters.
Undoubtedly, the structure of a thermostabilised
Fig. 5. Amino acid residues in
LeuT equivalent to the thermostabi-
lising mutations in SAH6. (a) The
structure of LeuT (Protein Data
Bank code 3GWU) is depicted in
rainbow colouration (N-terminus,
blue; C-terminus, red) with the side
chains in equivalent positions to the
thermostabilisation mutations in
SAH6 shown as black spheres.
The view is from the extracellular
surface perpendicular to the mem-
brane plane. (b–d) The mutations
are found at helix–helix interfaces
and often at the sites of kinks
or unwound regions; (b) Gly416LeuT
(A505L SAH6 ) ; (c ) Leu25 LeuT
(L99A SAH6 ) ; (d ) A la195 LeuT
(G278ASAH6). Additional views of
the mutations are in Fig. S6, and for
the details of SAH7 mutations, see
Fig. S7.
2204 Thermostabilisation of SERTmammalian SERT mutant will be of most benefit to
enhance our understanding of the NSS family, and
this work is currently in progress.Materials and Methods
Materials
All radiolabelled ligands were purchased from PerkinEl-
mer and detergents were from Anatrace.
cDNA clones and mutagenesis
The construct c-Myc-SERT-mCherry-BioHis10 was de-
veloped from the SERT cDNA in plasmid pCGT13728 and
inserted into the mammalian cell expression vector
pcDNA5/FRT/TO (Invitrogen), which was used for site-
directed mutagenesis and expression. The plasmid
constructs used for stable expression of SERT-GFP,
SAH6-GFP and SAH7-GFP mutants were derived from
plasmid pCGT273,30 which was modified into SERT-GFP-
StrepII-His10 (pJMA111-SAH6 and pJMA111-SAH7).
Mutants were generated by PCR using the QuikChange
II methodology (Stratagene) using KOD Hot Start poly-merase (Novagen). PCR reactions were transformed into
XL1-competent cells (Stratagene), and every cDNA clone
was fully sequenced to ascertain the presence of only the
desired mutation. Mutations were combined by PCR as
above, but using multiple primers.
Transient transfection and generation of stable
cell lines
Plasmid DNA for each SERT-mCherry mutant was
amplified using a Maxi-prep kit (Qiagen) and transiently
transfected (GeneJuice, Novagen) into adherent mamma-
lian T-REx-293 cells (50% confluent) grown in Dulbecco's
modified Eagle's media supplemented with 10% tetracy-
cline-free fetal bovine serum and 5 μg/l blasticidin.
Expression of mutants was induced by addition of
0.8 μg/ml tetracycline and incubation at 37 °C for 24 h.
Stable cell lines expressing SAH6-GFP and SAH7-GFP in
T-REx-293 cells were generated by selection with media
containing 200 μg/ml zeocin.
Radiolabelled inhibitor binding assays
Saturation binding curves for membrane-bound SERT
were obtained using a range of [125I]RTI55 concentrations
from 0.13 nM to 160 nM in a 96-well plate format with
2205Thermostabilisation of SERTnonspecific binding being accounted for by incubating
identical samples with 1 μM cocaine. The samples were
incubated for 2 h at 30 °C and then filtered on 96-well
glass fibre plates (Millipore) pre-treated with 200 μl of 0.1%
polyethyleneimine. The filters were washed three times
with 200 μl ice-cold SERT buffer [100 mM NaCl and
20 mM Tris (pH 7.4)], dried for 1 h at 50 °C prior to liquid
scintillation counting. Competition binding assays were
performed as above, but a range of concentrations of
unlabelled ligand was included and a final concentration of
0.2 nM [125I]RTI55 was used.
The thermostability of detergent-solubilised [125I]RTI55-
bound SERT was determined as previously described
for GPCRs.5,6,8,9 Briefly, cells containing unpurified
SERT were incubated with 1 nM [125I]RTI55 for
30 min on ice, which were then solubilised with
detergent on ice for 30 min before incubation at varying
temperatures for 30 min. The radioligand bound to the
membrane protein was separated from free radioligand
by centrifugal gel filtration and the radioligand bound to
the eluted transporter measured by liquid scintillation
counting.[3H]5HT uptake assays
The [3H]5HT uptake assays were performed with slight
modifications to the method previously described.46 In
brief, T-REx-293 cells and T-REx-SERT cells were plated
onto poly-L-lysine-coated (1 mg/ml) 24-well plates, grown
to 80% confluency, induced by the addition of 0.8 μg/ml
tetracycline and grown for 48 h. The growth medium was
aspirated and the cells were washed once with TB buffer
[10 mM Hepes (pH 7.5), 150 mM NaCl, 2 mM KCl, 1 mM
CaCl2 and 1 mM MgCl2]. The assays were performed at
25 °C using one million cells in 400 μl TB buffer and 2 μM
[3H]5HT and terminated 3 min after addition of substrate
by three washes of ice-cold TB buffer containing 1 μM
paroxetine or 10 μM cocaine. [3H]5HT was released by
rupturing the cells with 2% SDS, which was quantified by
liquid scintillation counting. Nonspecific uptake was
defined as [3H]5HT transport in the presence of 10 μM
paroxetine or 10 μM cocaine.Acknowledgements
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